28 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
First Episode of Opportunistic ... Disease in HIV-AIDS ... Pneumocystis pneumonia (PCP ... HIVAIDS #IDSA #management ... #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
First Episode of Opportunistic ... Disease in HIV-AIDS ... Pneumocystis pneumonia (PCP ... HIVAIDS #IDSA #management ... #pharmacology
Initiation of ART in HIV patients with Opportunistic Infections
 • Pulmonary TB and CD4 cell count
Initiation of ART in HIV ... Infections • Pulmonary ... Antiretroviral #Therapy ... #HAART #HIV #Opportunistic ... #Infections #management
CNS Infection in HIV / AIDS - Differential Diagnosis Framework

Principles of HIV-Associated CNS Opportunistic Infections:
 •
antiretroviral therapy ... antiretroviral therapy ... antimicrobial therapy ... antiretroviral therapy ... Coccidioidomycosis • Histoplasmosis
Immune Reconstitution Inflammatory Syndrome - Overview of IRIS

What Is IRIS?
	• A state of hyperinflammatory response that
• 10-20% of HIV-infected ... Cutaneous lesions • Histoplasmosis ... Lymphadenitis, cutaneous histoplasmosis ... leukoencephalopathy (PML ... Differential #Diagnosis #Management
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Leishmaniasis in HIV-AIDS ... mm3 Preferred Therapy ... Prevention #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
Infections in HIV-AIDS ... /ml Preferred Therapy ... Prevention #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Infections in HIV-AIDS ... to 5 mg/kg/day IV ... Prevention #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
Candidiasis in HIV-AIDS ... 400 mg) PO or IV ... Prevention #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Isospora belli Infection in HIV-AIDS
Treating Isospora belli Infection
General Management Considerations:
 • Fluid
belli Infection in HIV-AIDS ... Infection General Management ... Prevention #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology